C4-carboxylic acid-substituted tryptamine derivatives and methods of using

1. A chemical compound having chemical formula (I):

wherein R 4 is a carboxylic acid moiety; and

wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group, wherein the carboxylic acid moiety has the chemical formula (II):

wherein R 4a is a halo-substituted phenyl group.

2. A chemical compound according to claim 1 , wherein the halo-substituted phenyl group is a bromo-substituted phenyl group.

3. A chemical compound according to claim 1 , wherein the halo-substituted phenyl group is a para-bromo-substituted phenyl group.

4. A chemical compound according to claim 1 , wherein the compound having chemical formula (I) the compound is C(I):

5. A pharmaceutical formulation comprising a chemical compound according to claim 1 , together with a pharmaceutically acceptable excipient, diluent, or carrier.

6. A pharmaceutical formulation according to claim 5 , wherein the pharmaceutical formulation is a pro-drug pharmaceutical formulation, wherein the compound having formula (I) is in vivo hydrolyzed to form a compound having chemical formula (VI):

wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group.

7. A method for treating a brain neurological disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a chemical compound according to claim 1 , wherein the pharmaceutical formulation is administered in an effective amount to treat the brain neurological disorder in the subject, wherein the disorder is a 5-HT 1A receptor mediated disorder, a 5-HT 2A receptor mediated disorder, a 5-HT 1B receptor mediated disorder, a 5-HT 2B receptor mediated disorder, a 5-HT 3A receptor mediated disorder, an ADRA1A receptor mediated disorder, an ADRA2A receptor mediated disorder, a CHRM1 receptor mediated disorder, a CHRM2 receptor mediated disorder, a CNR1 receptor mediated disorder, a DRD1 receptor mediated disorder, a DRD2S receptor mediated disorder, or an OPRD1 receptor mediated disorder, a MOA-1 enzyme mediated disorder, a dopamine active transporter (DAT) mediated disorder, a norephedrine transporter (NET) mediated disorder, or a serotonin transporter (SERT) transmembrane transport protein mediated disorder.

8. A method according to claim 7 , wherein upon administration the compound having formula (I) is in vivo hydrolyzed to form a compound having chemical formula (VI):

wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group,

and wherein the compound having chemical formula (VI) interacts with a receptor from the group consisting of 5-HT 1A receptor, a 5-HT 2A receptor, a 5-HT 1B receptor, a 5-HT 2B receptor, a 5-HT 3A receptor, an ADRA1A receptor, an ADRA2A receptor, a CHRM1 receptor, a CHRM2 receptor, a CNR1 receptor, a DRD1 receptor, a DRD2S receptor, and an OPRD1 receptor to thereby modulate the receptor in the subject and exert a pharmacological effect.

9. A method according to claim 7 , wherein upon administration the compound having formula (I) is in vivo hydrolyzed to form a compound having chemical formula (VI):

wherein R 3a and R 3b are each a methyl group,

and wherein the compound having chemical formula (VI) interacts with a transmembrane transport protein from the group consisting of a dopamine active transporter (DAT), a norephedrine transporter (NET), and a serotonin transporter (SERT) transmembrane transport protein to thereby modulate the transmembrane transport protein in the subject and exert a pharmacological effect.

10. A method for in vivo or in vitro modulating (i) a receptor selected from 5-HT 1A receptor, a 5-HT 2A receptor, a 5-HT 1B receptor, a 5-HT 2B receptor, a 5-HT 3A receptor, an ADRA1A receptor, an ADRA2A receptor, a CHRM1 receptor, a CHRM2 receptor, a CNR1 receptor, a DRD1 receptor, a DRD2S receptor, or an OPRD1 receptor; (ii) an enzyme, the enzyme being MOA-1; or (iii) a transmembrane transport protein selected from a dopamine active transporter (DAT), a norephedrine transporter (NET), or a serotonin transporter (SERT) transmembrane transport protein, the method comprising contacting (i) the 5-HT 1A receptor, the 5-HT 2A receptor, the 5-HT 1B receptor, the 5-HT 2B receptor, the 5-HT 3A receptor, the ADRA1A receptor, the ADRA2A receptor, the CHRM1 receptor, the CHRM2 receptor, the CNR1 receptor, the DRD1 receptor, the DRD2S receptor, or the OPRD1 receptor; (ii) MOA-1; or (iii) the dopamine active transporter (DAT), the norephedrine transporter (NET), or the serotonin transporter (SERT) transmembrane transport protein with a chemical compound according to claim 1 under reaction conditions sufficient to modulate (i) the 5-HT 1A receptor, the 5-HT 2A the 5-HT 1B receptor, the 5-HT 2B receptor, the 5-HT 3A receptor, the ADRA1A receptor, the ADRA2A receptor, the CHRM1 receptor, the CHRM2 receptor, the CNR1 receptor, the DRD1 receptor, the DRD2S receptor, or the OPRD1 receptor; (ii) MOA-1; or (iii) the dopamine active transporter (DAT), the norephedrine transporter (NET), or the serotonin transporter (SERT) transmembrane transport protein, wherein the in vivo modulation comprises the administration of the chemical compound to a mammalian subject, optionally a human subject, and wherein the in vitro modulation comprises contacting the chemical compound with a sample containing the receptor or the enzyme or the transmembrane transport protein.

11. A pharmaceutical formulation comprising a chemical compound according to claim 4 , together with a pharmaceutically acceptable excipient, diluent, or carrier.

12. A pharmaceutical formulation according to claim 11 , wherein the pharmaceutical formulation is a pro-drug pharmaceutical formulation, wherein the compound having formula (I) is in vivo hydrolyzed to form a compound having chemical formula (VI):

wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group.

13. A method for treating a brain neurological disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a chemical compound according to claim 4 , wherein the pharmaceutical formulation is administered in an effective amount to treat the brain neurological disorder in the subject, wherein the disorder is a 5-HT 1A receptor mediated disorder, a 5-HT 2A receptor mediated disorder, a 5-HT 1B receptor mediated disorder, a 5-HT 2B receptor mediated disorder, a 5-HT 3A receptor mediated disorder, an ADRA1A receptor mediated disorder, an ADRA2A receptor mediated disorder, a CHRM1 receptor mediated disorder, a CHRM2 receptor mediated disorder, a CNR1 receptor mediated disorder, a DRD1 receptor mediated disorder, a DRD2S receptor mediated disorder, or an OPRD1 receptor mediated disorder, a MOA-1 enzyme mediated disorder, a dopamine active transporter (DAT) mediated disorder, a norephedrine transporter (NET) mediated disorder, or a serotonin transporter (SERT) transmembrane transport protein mediated disorder.

14. A method for treating a brain neurological disorder according to claim 13 , wherein the disorder is a 5-HT 2A receptor mediated disorder.

15. A method of making a chemical compound having chemical formula (I):

wherein R 4 is a carboxylic acid moiety; and

wherein R 3a and R 3b are each a methyl group, wherein the carboxylic acid moiety has the chemical formula (II):

wherein R 4a is a para-bromo-substituted phenyl group,

wherein the method comprises the performance of chemical reactions selected from the group consisting of (i); (ii); (iii); (iv); (v); (vi); and (vii):

wherein in (i), (ii), (iii), (iv), (v), (vi), and (vii),

chemical reaction (a) is conducted in the presence of tetrabutylammonium fluoride (TBAF) under conditions sufficient to perform reaction (a);

chemical reaction (b) is conducted in the presence of N,N-diisopropylethylamine (DIPEA) under conditions sufficient to perform reaction (b);

chemical reaction (c) is conducted in the presence of palladium on carbon under hydrogen gas under conditions sufficient to perform reaction (c);

chemical reaction (d) is conducted in the presence of potassium hexamethyldisilazide (KHMDS) and triisopropylsilyl chloride (TIPSCl) under conditions sufficient to perform reaction (d);

chemical reaction (e) is conducted in the presence of lithium aluminum hydride (LiAlH 4 ) under conditions sufficient to perform reaction (e);

chemical reaction (f) is conducted in the presence of dimethylamine under conditions sufficient to perform reaction (f); and

chemical reaction (g) is conducted in the presence of oxalyl chloride under conditions sufficient to perform reaction (g).